摘要
目的探讨替米沙坦对糖尿病大鼠血脂代谢及免疫功能的影响机制。方法建立糖尿病大鼠模型;将50大鼠分为对照组、模型组、替米沙坦组、TGF-β1抑制剂组、TGF-β1激活剂组,每组10只,喂养至第12周,统一处理大鼠;血糖分析仪检测各组大鼠的血糖水平;全自动生化仪检测各组大鼠的血脂水平;流式细胞中检测各组大鼠血清中CD4^+、CD8^+、CD4^+/CD8^+的水平;ELISA实验检测血清中IL-6、IL-2的表达水平;Western blot检测各组大鼠肾脏组织中TGF-β1、p-Smad2/3蛋白表达。结果与对照组相比,模型组大鼠血糖含量、TG、TC、CD8^+、IL-6均显著升高,HDL-C、CD4^+、CD4^+/CD8^+、IL-2均显著降低(P<0.05);替米沙坦、TGF-β1抑制剂均可改善糖尿病大鼠的血糖血脂及T淋巴细胞免疫水平;TGF-β1激活剂可逆转替米沙坦对糖尿病模型大鼠血脂代谢及T淋巴细胞免疫功能的作用。结论替米沙坦对糖尿病大鼠血脂代谢及免疫功能具有改善作用,其机制与失活TGF-β1/Smad2/3信号通路有关,为替米沙坦用于糖尿病的治疗提供理论依据。
This study was designed to investigate the effects of telmisartan on blood lipid metabolism and immune function in diabetic rats.Diabetic rat model was established,and 50 rats were divided into control group, model group,telmisartan group,TGF-β1 inhibitor group and TGF-β1 activator group,with 10 rats in each group. Twelve weeks later,the rats were sacrificed for detecting the blood glucose level by blood glucose analyzer,the blood lipid level by automatic biochemical analyzer,the serum CD4^+,CD8^+,CD4^+/CD8^+ levels by flow cytometry,the IL-6 and IL-2 levels by ELISA,and the protein expression of TGF-β1 and p-Smad2/3 by Western blotting.Compared with the control group,blood glucose,TG,TC,CD8^+ and IL-6 in the model group were significantly increased,while HDL-C,CD4^+,CD4^+/CD8^+ and IL-2 were significantly decreased (P<0.05).Telmisartan or TGF-β1 inhibitors could improve blood glucose,lipid and T lymphocyte immunity in diabetic rats.TGF-β1 activator can reverse the effects of telmisartan on blood lipid metabolism and T lymphocyte immune function in diabetic rats.In conclusion, telmisartan can improve the lipid metabolism and immune function of diabetic rats.The mechanism may relate to the inactivation of TGF-β1/Smad2/3 signaling pathway, which provides a theoretical basis for telmisartan treatment for diabetes.
作者
陈伟
杨蓉
袁海胜
李卫峰
谢林伸
CHEN Wei;YANG Rong;YUAN Haisheng;LI Weifeng;XIE linshen(Department of Endocrinology and Nephrology,363 Hospital Affiliated to Southwest Medical University,Chengdu 610041,China;Graduate Faculty,West China School of Medicine,Sichuan University,Chengdu 610041,China;Department of Pathology,363 Hospital Affiliated to Southwest Medical University,Chengdu 610041,China;BloodPurification Center,West China Forth University Hospital,Sichuan University,Chengdu 610041,China)
出处
《免疫学杂志》
CAS
CSCD
北大核心
2019年第9期767-772,779,共7页
Immunological Journal
